Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

104
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
104
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

317
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
317
Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time01:02

Noncompartmental Analysis: Mean Transit, Absorption and Dissolution Time

69
When drugs are administered extravascularly, a comprehensive evaluation through noncompartmental analysis becomes imperative. This analytical approach considers various parameters that play a crucial role in understanding the pharmacokinetics of these drugs.
One of the key parameters is the mean transit time (MTT), which refers to the total duration required for drug molecules to transit through the body. MTT is determined by calculating the ratio of the area under the moment curve to the area...
69
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

440
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
440
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

175
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
175
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

954
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
954

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Matrix-Driven Modulation of Phenolic Profiles from <i>Euterpe oleracea</i> and <i>Oenocarpus bacaba</i> Using Natural Deep Eutectic Solvents.

Molecules (Basel, Switzerland)·2026
Same author

Influence of Tramadol on the Intravenous Pharmacokinetics of Dipyrone Active Metabolites in Dogs.

Journal of veterinary pharmacology and therapeutics·2026
Same author

Oxidative Stress Biomarkers in the Shrimp Macrobrachium amazonicum (Heller, 1862): Assessment in an Environmental Preservation Area in the Brazilian Amazon.

Environmental toxicology·2026
Same author

Effect of Calafate (<i>Berberis microphylla</i>) Intake on Plasma Atherogenic Indices in Rats With High-Sucrose Diet-Induced Obesity.

Journal of nutrition and metabolism·2026
Same author

Physiological and behavioural effects of continuous remifentanil-xylazine administration in donkeys.

Equine veterinary journal·2025
Same author

<i>Momordica charantia</i> L. (Cucurbitaceae) Leaf Extract from Phytochemical Characterization and Toxicity Evaluation to Modulation of Pro-Inflammatory Cytokines and MAPK/NFκB Pathways.

Molecules (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jun 16, 2025

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

18.7K

Pharmacokinetic Profile of Two Active Dipyrone Metabolites, 4-Methylaminoantipyrine (MAA) and 4-Aminoantipyrine (AA),

Andressa N Mouta1, Kathryn N Arcoverde1, Naftáli S Fernandes1

  • 1Departamento de Ciência Animal, Universidade Federal Rural do Semi-Árido (UFERSA), Mossoró 59625-900, RN, Brazil.

Animals : an Open Access Journal From MDPI
|June 13, 2025
PubMed
Summary

This study investigated dipyrone metabolism in dogs, identifying distinct slow and normal metabolizer groups for 4-methylaminoantipyrine. Results show significant differences in half-life, suggesting varied drug responses and the need for further pharmacogenetic research.

Keywords:
analgesiachromatographymetabolismmetamizole

More Related Videos

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.6K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.7K

Related Experiment Videos

Last Updated: Jun 16, 2025

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

18.7K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.6K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.7K

Area of Science:

  • Veterinary Pharmacology
  • Drug Metabolism
  • Pharmacokinetics

Background:

  • Dipyrone is a widely used analgesic and antipyretic in veterinary medicine.
  • Understanding its active metabolites, 4-methylaminoantipyrine (MAA) and 4-aminoantipyrine (AA), is crucial for optimizing therapeutic use in dogs.
  • Individual variability in drug metabolism can impact efficacy and safety.

Purpose of the Study:

  • To determine the pharmacokinetic profile of MAA and AA after intravenous dipyrone administration in dogs.
  • To identify potential differences in metabolite pharmacokinetics among individual dogs.
  • To assess the duration of metabolite detectability and relate it to potential therapeutic effects.

Main Methods:

  • Intravenous administration of dipyrone (25 mg·kg-1) to eleven mixed-breed dogs.
  • Serial blood sampling over 48 hours post-administration.
  • Quantification of MAA and AA plasma concentrations using ultra-performance liquid chromatography coupled to mass spectrometry (UPLC-MS/MS).
  • Pharmacokinetic analysis using PKSolver 2.0 and GraphPad Prism 10, including Principal Component Analysis for MAA.

Main Results:

  • Two distinct groups of MAA metabolizers were identified: slow metabolizers (SM) and normal/rapid metabolizers (NM).
  • Significant differences in half-life (T½) and mean residence time (MRT0-inf obs) were observed between SM and NM groups for MAA.
  • SM group: T½ = 44.44 ± 11.74 h, MRT0-inf obs = 32.62 ± 16.53 h; NM group: T½ = 11.25 ± 5.37 h, MRT0-inf obs = 7.44 ± 4.25 h.
  • The maximum concentration (Cmax) of AA was 2.80 ± 1.43 µg mL-1.
  • MAA was detectable in all dogs for 48 hours, while AA was detectable for up to 48 hours in seven dogs.

Conclusions:

  • Dipyrone administration results in detectable plasma concentrations of its active metabolites, MAA and AA, in dogs for extended periods.
  • The identification of distinct MAA metabolizer groups suggests significant inter-individual pharmacokinetic variability.
  • These findings support the potential for dipyrone to achieve therapeutic concentrations associated with cyclooxygenase inhibition with a favorable safety profile in dogs, but highlight the need for further pharmacogenetic and pharmacotherapeutic studies.